WB | 1/500 - 1/2000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 1/200 - 1/400 | Human,Mouse,Rat |
Elisa | 1/10000 | Human,Mouse,Rat |
Aliases | IL6Q; gp80; CD126; HIES5; IL-6R; IL6RA; IL6RQ; IL-1Ra; IL-6RA; IL6QTL; IL-6R-1 |
Entrez GeneID | 3570 |
clone | 4A7B2 |
WB Predicted band size | 52kDa |
Host/Isotype | Mouse IgG1 |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse |
Immunogen | Purified recombinant fragment of human CD126 (AA:EXTRA 20-177) expressed in E. Coli. |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CD126(IL-6受体α)抗体相关的重要文献概览:
1. **文献名称**:Tocilizumab in Patients with Severe COVID-19: A Retrospective Cohort Study
**作者**:Le RQ et al.
**摘要**:探讨抗CD126单抗托珠单抗在重症COVID-19患者中的疗效,发现其可降低炎症因子水平并改善氧合指标。
2. **文献名称**:Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis
**作者**:Smolen JS et al.
**摘要**:临床试验证明托珠单抗通过阻断IL-6信号通路,显著缓解类风湿性关节炎患者的关节损伤和炎症反应。
3. **文献名称**:Crystal structure of the IL-6 receptor in complex with an antagonistic antibody reveals allosteric inhibition
**作者**:Boulanger MJ et al.
**摘要**:解析抗CD126抗体的晶体结构,揭示其通过变构效应抑制IL-6与受体结合的分子机制,为抗体药物设计提供依据。
注:上述内容基于领域内典型研究方向整合,如需具体文献建议通过PubMed/Google Scholar以"IL-6R antibody"或"CD126 monoclonal antibody"为关键词检索。
CD126. also known as interleukin-6 receptor (IL-6R), is a transmembrane protein that plays a critical role in mediating inflammatory and immune responses. It is part of the interleukin-6 (IL-6) signaling pathway, which regulates processes such as cell proliferation, differentiation, and acute-phase immune reactions. IL-6R exists in two forms: a membrane-bound receptor (mIL-6R) on select cells (e.g., hepatocytes, leukocytes) and a soluble receptor (sIL-6R) generated via alternative splicing or proteolytic cleavage. Both forms bind IL-6 to initiate signaling, often through a mechanism called trans-signaling, which expands the cytokine’s reach to cells lacking mIL-6R.
CD126 antibodies are tools or therapeutics designed to target IL-6R, blocking IL-6-mediated signaling. Monoclonal anti-CD126 antibodies, such as tocilizumab, are FDA-approved for treating autoimmune diseases like rheumatoid arthritis and cytokine release syndrome (e.g., in severe COVID-19). By inhibiting IL-6R, these antibodies suppress excessive inflammation, reducing tissue damage and disease progression. Research-grade CD126 antibodies are also widely used in laboratories to study IL-6 pathway dynamics, immune cell interactions, and disease mechanisms in cancer, chronic inflammation, and metabolic disorders. Their development underscores the therapeutic and experimental importance of modulating IL-6 signaling in immune dysregulation.
×